Small-scale Bioreactors Market (2025 - 2035)

Small-Scale Bioreactors Market Size and Share Forecast Outlook (2025 to 2035)

The small-scale bioreactors industry will be valued at USD 2.55 billion by 2025 end. As per FMI's analysis, small-scale bioreactors will grow at a CAGR of 14.8% and reach USD 9.10 billion by 2035.

In 2024, the industry saw significant development, especially in technological advancement. Companies unveiled bioreactors with improved automation and control systems, greatly enhancing the optimization and efficiency of the process.

These innovations catered to the rising need for cost-efficient and scalable methods of biopharmaceutical research, enabling companies to simplify production and minimize operating complexity.

There was a noticeable trend towards the use of single-use bioreactors, mainly because they can minimize the threat of cross-contamination and optimize turnaround times. This was strongly in evidence within the contract research organizations (CROs) and contract manufacturing organizations (CMOs), which required agile manufacturing capacity in order to service a wide variety of bioprocessing requirements. The ease and efficiency of single-use bioreactors proved appealing, leading to increased uptake across the board.

Region-wise, North America continued to be at the forefront of the industry, aided by immense investments being made in biopharmaceutical R&D.

In parallel, the Asia Pacific region was a major growth influencer with its growing pharmaceutical sectors and robust government support for biotechnology research. This development at a fast pace made Asia Pacific a significant influencer in the worldwide industry.

Looking forward to 2025 and beyond, the industry will continue its firm growth trajectory. The growing emphasis on personalized medicine will probably stimulate the demand for small-scale bioreactors since such systems are critical for creating tailor-made therapies in small batches. This trend is consistent with the overall industry shift towards more targeted and individualized therapies.

Gene and cell therapy advancements are also going to widen the scope of application for products. With the rising popularity of these therapies, demand for scalable and flexible manufacturing processes will grow, further driving the industry. Furthermore, the use of continuous manufacturing processes is also expected to grow, with products allowing for smooth production, enhancing efficiency, and maintaining consistent quality of the product.

Key Metrics

Metrics	Values
Industry Size (2025E)	USD 2.55 billion
Industry Value (2035F)	USD 9.10 billion
Value-based CAGR (2025 to 2035)	14.8%

FMI Survey on Small-Scale Bioreactors Industry

FMI Survey Findings: Trends Stakeholder Insights

Surveyed Q4 2024, n=500 stakeholder respondents representing an even split between bioreactor producers, biopharmaceutical companies, contract research organizations (CROs), and contract manufacturing organizations (CMOs) in the USA, Western Europe, Japan, and South Korea

Primary Concerns of Stakeholders

• Process Scalability & Efficiency: 80% of stakeholders worldwide mentioned process scalability and operational efficiency as a critical concern in bioreactor choice.
• Automation & Real-Time Monitoring: 74% underscored the importance of combined automation and real-time monitoring to streamline production and quality control.

Regional Variance

• USA: 69% favored single-use bioreactors to increase operational agility and minimize contamination risks, versus 45% in Japan.
• Western Europe: 88% cited sustainability (biodegradable or recyclable bioreactor parts) as a critical driver, compared to 52% in the USA.
• Japan/South Korea: 61% concerned with space-saving bioreactor design owing to scarce lab and production space, versus 30% in the USA.

Embracing Sophisticated Technologies

High Variance

• USA: 57% of biopharmaceutical companies have embraced AI-enabled process optimization for bioreactors, driven by the need for accuracy in drug production.
• Western Europe: 50% have coupled bioreactors with automated control systems, led by Germany (63%) because of stringent regulatory requirements for process validation.
• Japan: Just 23% have installed high-tech bioreactors due to the high costs and undue complexity for small-scale biotech companies.
• South Korea: 36% have bought bioreactors with IoT-capable real-time monitoring, especially in Seoul's biotech clusters.

Divergent ROI Views

70% of USA stakeholders concluded that investment in automation was highly profitable, whereas 42% in Japan continued to use manually controlled bioreactors due to cost considerations.

Material & Bioreactor Type Choices

Consensus

Glass Bioreactors: Chosen by 66% of stakeholders due to long-term reusability and better control in experimental setups.

Regional Variation

• Western Europe: 53% chose stainless steel for durability and meeting high-quality standards compared to 35% worldwide.
• Japan/South Korea: 42% utilized hybrid polymer-glass models in order to combine affordability with sterility, especially among biotech startups.
• USA: 72% went with single-use bioreactors, but there was a 30% preference by academic institutions for reusable glass models.

Price Sensitivity & Investment Trends

Shared Challenges

89% mentioned rising raw material prices (stainless steel 28% higher, polymer materials 22% higher) as a significant industry challenge.

Regional Variations

• USA & Western Europe: 61% of companies were prepared to pay a 15-25% premium for advanced automation and process analytics.
• Japan/South Korea: 76% were interested in cost-effective bioreactor models (
• South Korea: 47% favored leasing models to control initial expenses, versus 20% in the USA.

Pain Points in the Value Chain

Manufacturers

• USA: 56% were challenged by supply chain interruptions to the availability of high-quality bioreactor materials.
• Western Europe: 49% mentioned complicated regulatory approval procedures (e.g., EU GMP standards).
• Japan: 59% indicated sluggish demand due to biotech startup financial limitations.

Distributors

• USA: 68% were plagued by stock shortages due to dependence on imported pieces.
• Western Europe: 54% faced competition from lower-cost Eastern European suppliers.
• Japan/South Korea: 64% mentioned logistical difficulties in shipping bioreactors to rural biotech clusters.

End-Users (Pharmaceutical & Biotech Companies, CROs, CMOs)

• USA: 45% mentioned high maintenance costs as a leading challenge in reusable bioreactors.
• Western Europe: 40% encountered integration challenges when implementing new bioreactors into legacy manufacturing systems.
• Japan: 57% encountered limited technical support for troubleshooting sophisticated bioreactors.

Future Investment Priorities

Alignment

73% of the world's manufacturers intend to spend money on next-generation bioreactors with AI and data analysis.

Regional Differences

• USA: 62% on modular bioreactors for multi-use (e.g., fermentation + cell culture).
• Western Europe: 56% investing in green biomanufacturing (e.g., energy-saving bioreactors).
• Japan/South Korea: 50% emphasizing compact bioreactor design (e.g., benchtop and micro-scale designs).

Regulatory Impact

USA

67% reported FDA's changing regulations on bioprocessing as a major compliance issue.

Western Europe

80% considered EU's Pharma Manufacturing Sustainability Initiatives to be the driver for green bioreactors adoption.

Japan/South Korea

34% only believed rules significantly influenced by decisions, stating lax enforcement policy.

Conclusion: Consensus vs. Variance

High Consensus

Requirements of scalability, automation, and cost control persist everywhere.

Most important Variances

• USA: Resolute initiative towards single-use bioreactors vs. Japan/South Korea: Cost-preference for straightforward models.
• Western Europe: Innovation leadership in sustainability & green bioreactors vs. Asia: Emphasis on pragmatic material selections.

Strategic Insight

A one-size-fits-all approach will not be successful in the international bioreactor industry. Solutions that are custom-designed-single-use in the USA, stainless steel in Europe, and compact models in Asia-are essential to entry.

Government Regulations on Small-Scale Bioreactors Industry

Country/Region	Regulatory Impact & Mandatory Certifications
USA	FDA's Current Good Manufacturing Practices (cGMP): All bioreactors used in drug production must comply with FDA cGMP standards to ensure quality, sterility, and safety. Biologics Control Act & FDA Guidelines: Biopharmaceutical manufacturers using bioreactors must meet stringent regulatory requirements for biologic drug production. Environmental Protection Agency (EPA) Regulations: Companies must adhere to waste disposal guidelines, particularly for single-use bioreactors
Western Europe	EU Good Manufacturing Practice (EU GMP): All bioreactor-based production must comply with GMP regulations, ensuring consistency and quality in biopharmaceuticals. European Medicines Agency (EMA) Guidelines: Mandatory compliance for firms producing advanced biologics, including monoclonal antibodies and gene therapies. REACH (Registration, Evaluation, Authorisation, and Restriction of Chemicals): Ensures that materials used in bioreactors (e.g., stainless steel, polymers) are safe and sustainable. ISO 13485 Certification: This is required for companies producing medical devices, including bioreactors used in cell therapy and regenerative medicine.
Germany	Stricter GMP Compliance: Germany has some of the most rigorous GMP compliance requirements in the EU. BFAR M (Federal Institute for Drugs and Medical Devices) Oversight: Regulates the use of bioreactors in pharmaceutical applications, ensuring adherence to national and EU laws.
UK	MHRA (Medicines and Healthcare Products Regulatory Agency): Post-Brexit, the UK maintains its own regulatory framework but closely follows EU GMP and EMA guidelines. CE Marking Requirements: Bioreactors used in pharmaceutical production must have CE marking for legal sale in the UK.
France	ANSM (French National Agency for Medicines and Health Products Safety): Regulates bioreactor-based drug production, ensuring compliance with EU GMP and national safety laws.
Japan	PMDA (Pharmaceuticals and Medical Devices Agency): Regulates bioreactors used in drug manufacturing, ensuring they meet Japan’s Pharmaceutical Affairs Act. Japan GMP Compliance: Requires adherence to global GMP standards, but with additional national requirements for documentation and quality assurance. JIS (Japanese Industrial Standards) Certification: This may be required for bioreactor materials and components.
South Korea	MFDS (Ministry of Food and Drug Safety): Enforces compliance with GMP regulations for biopharmaceutical production. Biotechnology Promotion Act: Encourages biotech innovation, offering subsidies and tax benefits for companies investing in advanced bioreactor technologies.
China	NMPA (National Medical Products Administration): Governs the production and use of bioreactors in pharmaceutical manufacturing, aligning with global GMP standards. Made in China 2025 Policy: Promotes domestic bioreactor production, leading to increased local manufacturing standards and investments.

Market Analysis

The industry is in a high-growth phase, fueled by increasing demand for biologics, personalized medicine, and next-generation biomanufacturing technologies. Firms that are investing in automation, single-use technologies, and process scalability-especially in biopharmaceuticals and contract manufacturing-are likely to benefit the most, while companies that are lagging in responding to regulatory changes and cost pressures are likely to suffer. As the industry transitions to continuous and data-driven bioprocessing, innovation and compliance will be essential to sustaining a competitive edge.

Top 3 Strategic Imperatives for Stakeholders

Drive Adoption of Automated and Single-Use Bioreactors

Actionable Recommendation: Invest in R&D and manufacturing capabilities for single-use bioreactors and automation-based systems to address the increasing need for flexibility, cost-effectiveness, and contamination-free bioprocessing. Companies must focus on incorporating IoT and AI-based monitoring to improve process control and scalability.

Align with Personalized Medicine and Advanced Biologics Growth

Actionable Recommendation: Enhance partnerships with biotech companies and contract development and manufacturing organizations (CDMOs) to enable personalized medicine, gene therapies, and monoclonal antibody manufacturing. Customizing bioreactor solutions for small-batch, high-precision processes will be key to remaining competitive in this new landscape.

Increase Global Reach Through Strategic Partnerships and Compliance Readiness

Actionable Recommendation: Establish alliances with biopharmaceutical companies, regulatory agencies, and local distributors to tap high-growth, especially in the Asia-Pacific and Europe. Maintaining compliance with changing GMP and biopharma regulations (FDA, EMA, NMPA) will be important to gain access to industries and maintain long-term competitive edge.

Top 3 Risks Stakeholders Should Monitor

Risk	Probability/Impact
Regulatory Uncertainty & Compliance Challenges-Frequent updates to global GMP and biopharmaceutical regulations (FDA, EMA, NMPA) may delay product approvals and entry.	High
Supply Chain Disruptions & Raw Material Shortages-Dependence on specialized components (e.g., sensors, single-use plastics) could lead to production bottlenecks and cost escalations.	Medium
Technological Obsolescence & Competitive Pressure-Rapid advancements in bioprocessing technologies could render existing systems outdated, forcing companies to accelerate R&D investments.	Medium

Executive Watchlist

Priority	Immediate Action
Scaling Single-Use Bioreactor Production	Run a feasibility study on expanding single-use bioreactor manufacturing to meet rising demand in biologics and personalized medicine.
Regulatory Readiness & Compliance Alignment	Initiate a proactive compliance audit for upcoming FDA, EMA, and NMPA regulatory changes to ensure seamless access.
Strategic Expansion in APAC & Europe	Launch regional partnership initiatives with CDMOs and biopharma firms to accelerate penetration in high-growth regions.

For the Boardroom

To stay ahead, companies to stay ahead in the rapidly evolving industry, the company must accelerate investments in single-use bioreactor technology, automation, and AI-driven bioprocess monitoring to meet the surging demand for personalized medicine and advanced biologics. Regulatory compliance must be preemptively aligned with evolving FDA, EMA, and NMPA standards to avoid bottlenecks in expansion.

Additionally, targeted partnerships with CDMOs and biopharma firms in APAC and Europe will be crucial for capturing high-growth opportunities. The roadmap should prioritize scalability, flexibility, and rapid adaptation to new biomanufacturing trends, ensuring a first-mover advantage in next-generation bioprocessing solutions.

Segment-wise Analysis

By Product

Single-use bioreactors (SUBs) are now being preferred over reusable bioreactors more and more, particularly in the biopharmaceutical and biotech sectors. The reason for this shift is their flexibility, cost-effectiveness, and lower risk of contamination.

Unlike the conventional stainless-steel reusable bioreactors that need rigorous cleaning and sterilization between runs, single-use systems avoid cross-contamination risks and greatly reduce turnaround time. This is especially useful to contract development and manufacturing organizations (CDMOs) and those companies that produce personalized medicine, where small batches and quick scalability are crucial.

By Capacity

The 250 mL to 3L scale is the most common for use in small-scale bioreactors because it is a middle ground between scalability and efficiency. 250 mL to 500 mL and 500 mL to 3L scale bioreactors are especially popular in cell culture, microbial fermentation, and initial biopharmaceutical development because they offer adequate working volume for process optimization without excessive expenditure.

These capacities are regularly applied in process development, media development, and early-stage clinical trials, enabling researchers to scale up experiments in an economical way prior to commercial or pilot-scale production.

By End-User

Pharmaceutical and biopharmaceutical entities are the leading consumers of small-scale bioreactors, following their widespread concentration on drug discovery, biologics manufacturing, and process scale-up. Such entities use small-scale bioreactors for microbial fermentation, cell culture, and initial-stage development of bioprocesses in the manufacture of monoclonal antibodies, vaccines, and gene therapies.

Given the increasing rate of personalized medication and sophisticated biologics requirements, biopharmaceutical industries are heavily investing in single-use bioreactors to provide responsive and contamination-free production.

Country-wise Analysis

Countries	CAGR
USA	15.5%
UK	13.8%
France	13.2%
Germany	14.5%
Italy	12.5%
South Korea	13.5%
Japan	12.8%
China	16.2%

USA

The USA will witness a CAGR of approximately 15.5% from 2025 to 2035, thus being one of the most remunerative industries. The United States leads the world in the biopharmaceutical sector with significant investments in biologics, cell and gene therapies, and personalized medicine. Availability of prime drug manufacturers such as Pfizer, Moderna, and Amgen, together with a strong network of Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs), drives demand for flexible single-use bioreactors.

Regulatory encouragement by the FDA, especially in speeding up biologics approvals, also spurs quick uptake of high-end bioprocessing technologies. The National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) ongoing support of biotech research also increases the chances of bioreactor manufacturers.

UK

The UK sector will grow at a CAGR of approximately 13.8% between 2025 and 2035, driven by the strong biopharma cluster of the nation and government-backed life sciences initiatives. The UK is a global leader in biotechnology research, with significant contributions from the UK BioIndustry Association (BIA) and the Medicines and Healthcare Products Regulatory Agency (MHRA), which offer regulatory assistance to new biologics and personalized medicine.

Increasing demand for cutting-edge biologics like monoclonal antibodies, mRNA medicines, and cell and gene therapies has escalated the demand for single-use bioreactors among academia research, biotech startups, and large pharma like AstraZeneca and GlaxoSmithKline (GSK).France

The French industry is projected to expand at a CAGR of around 13.2% during 2025 to 2035, driven primarily by its thriving pharmaceutical and biotech industries. France has a well-developed biopharmaceutical sector, with Sanofi and Servier, the big players, investing significantly in the production of biologics. Additionally, government-funded initiatives like the France 2030 plan and tax credits for R&D in biotech are propelling rapid innovation in biomanufacturing and single-use bioprocessing technology.

France is also a center for cell and gene therapy research, with facilities like INSERM (French National Institute of Health and Medical Research) and Institut Pasteur leading the way in the innovation of bioprocess.

Germany

Germany is expected to observe strong growth, with a CAGR of 14.5% between 2025 and 2035, because of its status as the leader of the European biopharma and widespread adoption of advanced bioprocessing technology. The country boasts world-class biotechnology firms, contract producers, and large pharma players such as Bayer, BioNTech, and Merck KGaA that invest heavily in monoclonal antibody bioreactor technologies, gene therapies, and cell culture innovation.

Germany's investment in automation of biomanufacturing and integration with Industry 4.0 has accelerated the adoption of AI-based, single-use, and continuous bioprocessing systems.

Italy

Italy's low-volume bioreactors industry is estimated to grow at a CAGR of nearly 12.5% from 2025 to 2035, driven by its increasing biotech base and accelerated adoption of biopharmaceutical production technology. Italy has a strong footprint in biosimilars, vaccine production, and regenerative medicine, with Menarini and Chiesi Group leading biomanufacturing advancement.

The country is also observing rising investments in single-use bioreactor technologies by the front-runners that are led by contract manufacturers targeting global biopharma leaders.

South Korea

South Korea's low-volume bioreactors industry is expected to clock a CAGR of approximately 13.5% from 2025 to 2035, led by its rapidly growing biopharmaceutical sector, strong government initiatives, and increased investments in biosimilars and biologics. South Korea boasts global biotech titans such as Samsung Biologics, Celltrion, and SK Biopharmaceuticals, which are scaling up their biomanufacturing facilities aggressively.

The South Korean government has announced major plans such as the K-Bio Strategy and Bio Economy 2030 Plan to become a pioneer center for the R&D of biopharmaceuticals and cutting-edge bioprocessing technologies.

Japan

Japan's low-volume bioreactors industry is expected to register a CAGR of approximately 12.8% from 2025 to 2035, fueled by the country's advancements in regenerative medicine, personalized therapies, and cutting-edge bioprocessing technology. Japan has been at the forefront of the biotechnology revolution for decades, with heavyweights like Takeda Pharmaceuticals, Astellas, and Daiichi Sankyo heavily investing in next-generation biologics and robotic biomanufacturing technologies.

The Japanese government, via the Pharmaceuticals and Medical Devices Agency (PMDA), has offered regulatory incentives for biotech innovation and established Japan as a competitive industry for single-use bioreactors and continuous bioprocessing systems. Regenerative medicine, including stem cell and gene therapy research, has also generated demand for adaptable and scalable bioreactor systems in Japan.

China

China is also set to be the top industry, showing a CAGR of about 16.2% from 2025 to 2035 due to enormous growth in the biopharmaceutical sector, significant government investments, and an increasingly emerging biotech startup culture. The country rapidly became the world's hub for biomanufacturing in a matter of decades with the likes of WuXi Biologics, Innovent Biologics, and BeiGene leading colossal-scale biologics production.

The Made in China 2025 and Healthy China 2030 initiatives of the Chinese government have placed a push on biopharma R&D, biosimilars, and high-tech drug manufacturing, leading to an increasing demand for advanced bioreactor systems. The push for self-sufficiency in biomanufacturing has led to the increased adoption of locally produced single-use bioreactors and automation-driven bioprocessing solutions.

Market Share Analysis

Thermo Fisher Scientific (18%)

Thermo Fisher Scientific takes the lead in the industry through HyPerforma single-use bioreactors, benchtop, and scalable platforms. The company's automation and AI-driven real-time monitoring maximize bioprocess efficiency and render it the drugmaker's go-to choice, as well as CROs and research institutes.

Thermo Fisher has expanded its manufacturing footprint through acquisitions, including Patheon and Brammer Bio, extending its presence further in the segment of biologics manufacturing. Its international presence, particularly in Europe and North America, gives it a competitive advantage.

Sartorius AG (16%)

Sartorius AG holds a strong brand position in single-use bioreactors (SUBs) in the field of monoclonal antibody and vaccine production. Ambr and the BIOSTAT series of Sartorius provide modular and scalable offerings for biopharma and research activity. Sartorius is also increasing quickly in the Asia-Pacific region, particularly in China and South Korea, through localized production and R&D units to keep pace with increased demand in the region for dynamic bioprocessing solutions.

Eppendorf AG (13%)

Eppendorf AG is the leader in bench-scale and lab-scale bioreactors, and its BioFlo and DASbox find extensive use in universities, biotech companies, and research organizations. Eppendorf's strength comes in the form of simple-to-operate, space-saving, and affordable bioreactor systems for small-batch production and initial R&D. Eppendorf's focus on cloud-based remote monitoring further strengthens its position among research institutes seeking high-level data integration and automation.

Danaher Corporation (Cytiva & Pall Life Sciences) (12%)

Danaher Corporation and its subsidiaries, Cytiva and Pall Life Sciences, dominate biopharmaceutical and cell therapy manufacturing. FlexFactory and Xcellerex single-use bioreactors from the company deliver end-to-end continuous bioprocessing solutions, making it the first choice among CMOs and contract biomanufacturing organizations. Danaher has also created next-generation perfusion bioreactors, offering transparent scalability and real-time process monitoring, critical to the development of next-generation biologics.

Merck KGaA (MilliporeSigma) (10%)

Merck KGaA (MilliporeSigma) is a strong integrated bioprocessing solutions company with its Mobius® single-use bioreactors widely used in the manufacture of biopharmaceuticals. Its regulatory services and cGMP compliance enable it to be a trusted collaborator for pharma companies. Merck is also leading the development of continuous bioprocessing technologies, increasing production efficiency and downstream purification methods to increase biologic yield.

Key Players

• Sartorius AG
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher Corporation
• Lonza Group
• Eppendorf AG
• MiltenyiBiotec
• Getinge AB
• Solaris Biotechnology Srl
• Infors AG

Top Segments Studied in the Small-Scale Bioreactors Market Research Report

By Product:

With respect to the product, it is classified into reusable bioreactors and single-use bioreactors.

By Capacity:

In terms of capacity, it is divided into 5 ML to 100 ML, 100 ML to 250 ML, 250 ML to 500 ML, 500 ML to 1 L, 1 L to 3L, and 3 L to 5L.

By End-User:

In terms of end-users, it is divided into pharmaceutical & biopharmaceutical companies, CROs & CMOs, and academic & research institutes.

By Region:

In terms of region, it is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA.